Clinical data indicated that 14% of FL, 4% of MCL, and 2% of DLBCL patients showed aberrant overexpression of NKX6-3 (Table 1), indicating considerable deregulation in B-NHLs. The gene discussed is NKX6-3; the disease is diffuse large B-cell lymphoma.